Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimisation of Response for Organ Preservation in Rectal Cancer
NCT02514278Phase 3Completed
- Sponsor
- Centre Hospitalier Universitaire de Bordeaux
- Start
- Jan 2016
- Primary completion
- Jun 2022
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of FOLFIRINOX in rectal cancer, sponsored by Centre Hospitalier Universitaire de Bordeaux. Started Jan 2016; status: completed.
02
Drugs
FOLFIRINOX
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT02514278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02514278.